Novartis to pay $9.7B for US-based The Medicines
Switzerland-based Novartis agreed to buy US biotechnology firm The Medicines Company for $9.7 billion. Shareholders of Medicines will receive $85 per share in cash, a 24% premium over the closing price on November 22. Additionally, the price also represents a premium of 41% over the company’s 30-day volume weighted average price of $60.33 per share. […]
